Remove Generic Drugs Remove Genetics Remove Hormones
article thumbnail

Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data

XTalks

Sandostatin (Octreotide) Sandostatin 2022 sales: $1.238 billion Company/Developer: Novartis Date of first FDA approval: October 21, 1988 Indications Sandostatin is FDA-approved for: Sandostatin is a synthetic protein closely resembling the natural hormone somatostatin in the human body. million the drug made during the same time in 2022.

article thumbnail

Top 40 Best-Selling Cancer Drugs in 2023 by 2022 Data

XTalks

Sandostatin (Octreotide) Sandostatin 2022 sales: $1.238 billion Company/Developer: Novartis Date of first FDA approval: October 21, 1988 Indications Sandostatin is FDA-approved for: Sandostatin is a synthetic protein closely resembling the natural hormone somatostatin in the human body. million the drug made during the same time in 2022.